Filing Alert: Navidea Biopharmaceuticals Chapter 11
Navidea Biopharmaceuticals Files Chapter 11 in District of Delaware
Update (Oct. 7, 2025): A comprehensive case summary is now available for the Chapter 11 bankruptcy filing of Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc., a Columbus, OH-based biopharmaceutical company focused on precision immunodiagnostic agents and immunotherapeutics, filed for Chapter 11 protection on Oct. 1 in the U.S. Bankruptcy Court for the District of Delaware.
The company reports $1.2 million in assets and $12.9 million in liabilities. The filing indicates that there will be funds available for distribution to unsecured creditors. The case number is 25-11779.
Top Unsecured Claims
Key Parties
Counsel:
- Joseph C. Barsalona II
Pashman Stein Walder Hadyen, P.C.
Email: jbarsalona@pashmanstein.com
Signatories:
- Edward Burr – Independent Director
Claims Agent:
- Epiq Corporate Restructuring, LLC
Equity Security Holders:
- John K. Scott, Jr. – Approximately 54%
Bondoro Insights is continuing to monitor this case and will provide further coverage as appropriate.
Stay informed on every Chapter 11 bankruptcy case with liabilities exceeding $10 million. Subscribe for free to have our coverage delivered directly to your inbox, and explore our full archive of past summaries.
Explore Bondoro Insights for live case dockets and comprehensive coverage of material filings from petition to plan confirmation.
